{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:53:22Z","timestamp":1788252802235,"version":"build-2803163510"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["SNF_P2BEP3_191780"],"award-info":[{"award-number":["SNF_P2BEP3_191780"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>While the health hazards of synthetic cannabinoid receptor agonists (SCRAs) are often approximated using in vitro pharmacological parameters as surrogate, this approach fails to consider pharmacokinetic and pharmacodynamic complexity. This study aimed to develop a practical risk score for SCRAs prevalent in Germany between 2013 and 2021, based on prevalence data and differentiated data on intoxication cases in the same period of time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>The score integrates data from routine forensic serum\/blood and urine analysis and clinical data from a prospective study involving emergency department patients after consumption of new psychoactive substances (NPS) (symptoms and quantification data).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>SCRA prevalence data were obtained from a database query of routine serum\/blood and urine analyses conducted at the Institute of Forensic Medicine Freiburg (2013\u20132021). Intoxication case data were obtained from a prospective study of patients treated in German emergency departments and reported to the Poisons Information Center Freiburg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants\/Cases<\/jats:title>\n                    <jats:p>During the study period, 9929 serum\/blood and 45\u2009464 urine samples were routinely analysed for SCRAs. Forty\u2010eight non\u2010fatal intoxications with clinical symptoms were included, with written consent provided by participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>\n                      Twelve SCRAs were selected based on their prevalence. Quantification in serum\/blood and urine samples was conducted with liquid chromatography tandem mass spectrometry. The human cannabinoid receptor 1 affinities and activities were assessed using a competitive radioligand binding assay with [\n                      <jats:sup>3<\/jats:sup>\n                      H]CP\u201055940 and the functional [\n                      <jats:sup>35<\/jats:sup>\n                      S]GTP\u03b3S assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>From 2013 to 2021, 1633 serum\/blood and 8030 urine samples tested positive for one or more SCRAs (positive rate serum\/blood: 16.5%; urine: 17.7%). The risk score comprises three parts: (1) SCRA prevalence in routine case samples relative to the occurrence of intoxication cases in a certain time\u2010frame; (2) the Poison Severity Score; and (3) Toxicological Significance Score, to account for the extent to which each substance contributed to the observed clinical symptoms and consequently to the overall intoxication. The higher the risk score value, the greater the associated toxicological risk of an SCRA in the test set. Risk score values ranged from 9.9 (5F\u2010PB\u201022) to 3.1 (5F\u2010Cumyl\u2010PEGACLONE). No inverse relationship was observed between the risk score ranking and the receptor affinity or activity values based on visual comparison of the respective plots.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In vitro potency of synthetic cannabinoid receptor agonists (SCRAs) does not clearly correlate with harm potential, and hence other properties of the SCRAs seem to be involved. The risk score introduced here provides a novel framework for assessing the potential hazards of emerging SCRAs by integrating routine forensic data with clinical intoxication case analyses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.70268","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:24:53Z","timestamp":1766381093000},"page":"870-882","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well\u2010documented intoxication cases and basic pharmacological data"],"prefix":"10.1111","volume":"121","author":[{"given":"Michaela J.","family":"Sommer","sequence":"first","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg  Freiburg Germany"},{"name":"Hermann Staudinger Graduate School University of Freiburg  Freiburg Germany"},{"name":"Faculty of Medicine University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3647-7455","authenticated-orcid":false,"given":"Katharina Elisabeth","family":"Grafinger","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg  Freiburg Germany"},{"name":"Faculty of Medicine University of Freiburg  Freiburg Germany"},{"name":"Institute of Forensic Medicine, Forensic Toxicology and Chemistry University of Bern  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Hermanns\u2010Clausen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Freiburg  Freiburg Germany"},{"name":"Poisons Information Center, Department of General Pediatrics, Adolescent Medicine and Neonatology, Center for Pediatrics, Medical Center \u2013 University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Auw\u00e4rter","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg  Freiburg Germany"},{"name":"Faculty of Medicine University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3371"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2237"},{"key":"e_1_2_9_4_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).The challenge of new psychoactive substances: a report from the global SMART Programme. In: Crime UNOoDa editor. Vienna (Austria): UNODC; 2013."},{"key":"e_1_2_9_5_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).European Drug Report 2020: Trends and Developments. In: Addiction EMCfDaD editor. Luxembourg: Publications Office of the European Union;2020."},{"key":"e_1_2_9_6_1","unstructured":"European Union Drug Agency (EUDA).European Drug Report 2025: New psychoactive substances \u2013 the current situation in Europe. Luxembourg: Publications Office of the European Union;2025."},{"key":"e_1_2_9_7_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).European Drug Report 2014: Trends and Developments. Luxembourg: Publications Office of the European Union;2014."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3768\/rtipress.2011.op.0007.1111"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-015-1513-x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/29.5.394"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.645952"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.615318"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610300"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1505328"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkx031"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1110590"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-016-1812-x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.827"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2019.1580371"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1340648"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563659809028940"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2225"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3054"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108161"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110306"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2770"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-024-03830-2"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3035"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3038"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2607"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2517"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.9b00069"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.115.101980"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.08.008"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.557025"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1393082"},{"key":"e_1_2_9_37_1","unstructured":"AngererV S\u00fcssenbachF HirschingerN Auw\u00e4rterV.Validated LC\u2010MS\/MS method for qualitative and quantitative analysis of 75 synthetic cannabinoids in serum. The International Association of Forensic Science 2015; Florence Italy2015."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2016-0831"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3037"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-8719(02)00166-1"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.246983"},{"key":"e_1_2_9_42_1","doi-asserted-by":"crossref","unstructured":"Auw\u00e4rterV SommerM KaudewitzJ Hermanns\u2010ClausenM.Neue Entwicklungen auf dem NpS\u2010Markt. In: Deutscher Suchtkongress 2019. Stuttgart: Georg Thieme Verlag KG; 2019.","DOI":"10.1055\/s-0039-1696209"},{"key":"e_1_2_9_43_1","volume-title":"Handbuch Statistik, Methoden und Evaluation G\u00f6ttingen","author":"Holling H","year":"2010"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2870"},{"key":"e_1_2_9_45_1","doi-asserted-by":"crossref","unstructured":"CannaertA SparkesE PikeE Lin\u2010LuoJ FangA KevinR et al.Synthesis and in vitro cannabinoid receptor 1 (CB1) activity of recently detected synthetic cannabinoids 4F\u2010MDMB\u2010BICA (4F\u2010MDMB\u2010BUTICA) 5F\u2010MPP\u2010PICA (MPhP\u20102201) MMB\u20104en\u2010PICA (AMB\u20104en\u2010PICA MMB022) CUMYL\u2010CBMICA ADB\u2010BINACA (ADB\u2010BUTINACA) APP\u2010BINACA (APP\u2010BUTINACA) 4F\u2010MDMB\u2010BINACA (4F\u2010MDMB\u2010BUTINACA) MDMB\u20104en\u2010PINACA A\u2010CHMINACA 5F\u2010AB\u2010P7AICA 5F\u2010MDMB\u2010P7AICA and 5F\u2010AP7AICA.2020.","DOI":"10.1021\/acschemneuro.0c00644"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.6b02600"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70268","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.70268","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T04:19:06Z","timestamp":1774239546000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/add.70268"],"URL":"https:\/\/doi.org\/10.1111\/add.70268","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"2025-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}